StemCell Therapy

By now, we know the symptoms of COVID-19 to watch for:

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services.Policy

In addition to these, the CDC recommends seeking emergency medical care if you experience:

While the aforementioned symptoms seem to be more common, there have also been some outliers.

Throughout the pandemic, weve heard about COVID toes and rashes, pink eye and even people losing their appetite. So why does it seem like every time we turn around, some new symptom is making a special guest appearance?

According to pulmonary and critical care physician Joseph Khabbaza, MD, some of these reactions are quite normal, while others are symptoms that the medical community is still learning about.

Really, nothing is off the table when it comes to COVID. I always get texts from people asking if something theyre experiencing is normal. Well, theres nothing thats truly abnormal when it comes to COVID literally almost anything goes and we dont exactly know why, says Dr. Khabbaza.

Dr. Khabbaza says that two people who might appear to be similar on paper can react in totally different ways to COVID-19. As for uncommon symptoms of the virus, he says the following have popped up frequently.

Dr. Khabbaza reports that hes seen these symptoms quite often. While the medical community is still trying to figure out what causes brain fog, its believed that its likely a result of the bodys immune response to the virus or inflammation throughout the nervous system andblood vessels that lead to the brain. As for hallucinations and delirium, those, too, stem from the body fighting off the virus.

He explains.

Brain fog is kind of a big one. Its a kind of mental cloudiness like youre in a daze. You hear a lot about it with mild outpatients, but we also see it more severely in the ICU. Hallucinations and confusion are commonly experienced duringall sorts ofsevere illnesses. When you have a kind stressor like COVID-19 in the body, youre more likely to be confused, especially if you are elderly. This symptom is very common with older people as the body is trying to fight off an infection. COVID patients in the ICU sometimes experience a really bad delirium, worse than it seems with other patients who are critically ill. This delirium can worsen during a hospital stay when youre not sleeping normally or if youre in pain. Some medications that are used to keep patients comfortable on ventilators can even intensify delirium. With COVID-19, as someone gets worse, the type of brain manifestation that they experience can get worse as well. This can be due to a combination of blood flow and inflammation in the body or potentially alterations in blood flow at the microvascular level that cause these reactions.

Dr. Khabbaza says hes seen patients heart rates shoot up after minimal activity shortly after becoming infected. This along with elevated temperatures are a result of autonomic dysfunction.

Were seeing this more and more. When it occurs, our immune system is attacking autonomic nerves so nerves that regulate things in the body like heart rate and temperature that thermostat can be thrown off. When this occurs, peoples heart rates are not being regulated. Once you lose that balance, you can have a super-high heart rate or elevated temperature for no reason. Weve seen that in a lot of people and it seems to be an immune-mediated response, meaning the antibodies that you make somehow attack these kinds of nerves. Thats most likely playing a role in a lot of the unusual symptoms that were seeing, says Dr. Khabbaza.

Skin is the bodys largest organ, so it has the largest number of blood vessels. Dr. Khabbaza says skin irritations like rashes or discoloration isnt out of the ordinary when viruses or even autoimmune diseases are present.

When you think about it, anywhere where blood flows could be affected. Skin is the bodys largest organ so it has the most blood vessels. Its natural to see manifestations of illness in our skin. A lot of autoimmune diseases, in general, are associated with skin manifestations, especially viruses.

He adds that we can look back at our childhoods for evidence of this. Mainly, the rashes that developed during illness.

The skin is a place where a lot of things end up. If your blood count gets very low, your blood is too thick or you form tiny clots in the vessels, that sometimes can cause changes in your skins appearance.

While skin irritations arent as common, Dr. Khabbaza said theyre still something that the medical community is trying to understand as it battles COVID-19.

Loss of taste or smell have been associated with COVID-19, and while theyre alarming, Dr. Khabbaza says theres no need to panic if you experience these symptoms.

When this occurs, those senses are just not working normally. Nerves can be inflamed or secondarily irritated by our own immune system. But gradually with time, we should gain the ability to use them again.

Vocal cord neuropathy can occur when the nerves of the vocal cords are not working normally. This can often be a result of upper respiratory infections and can cause hoarseness or speaking problems, shortness of breath or swallowing issues. Dr. Khabbaza says this is mainly related to the vagus nerve being irritated and not working normally. This is the nerve that regulates digestion, heart rate, respiratory rate and reflex actions like coughing, sneezing and swallowing. Symptoms of vocal cord neuropathy, especially after a viral infection, often are first confused with post-viral asthma, but the symptoms often dont improve with the use of inhalers.

Dr. Khabbaza says experiencing one of these weird or unusual COVID symptoms isnt automatically a reason to panic, but if it does affect your ability to do daily activities, let your healthcare provider know sooner than later.

Most things are going to run their course and should gradually improve, but it can be a very slow process. If anything occurring is significantly affecting your daily living, your healthcare provider needs to know about it. If your heart rate shoots up to 170 when youre just walking down the hall, thats going to affect your ability to do anything, so thats something that warrants prompt attention. If a symptom is affecting your ability to work or your ability to accomplish your normal day-to-day activities, tell your healthcare provider. There may not always be some intervention that can be done, but COVID changes every day. We learn more every day and there are so many moving parts. If youre having difficulty, you always want to make sure your healthcare provider is aware of everything.

Continue reading here:
10 Unusual Symptoms of COVID-19 - Health Essentials from Cleveland Clinic

An extensive study of the product application and services conducted by subject matter experts assessing the Neuropathic Pain Market will help product owners to make a wise decision.

This press release was orginally distributed by SBWire

New York, NY -- (SBWIRE) -- 02/02/2021 -- The global research report titled 'Global Neuropathic Pain Market' recently published by Reports and Data is formulated with an aim to provide valuable insights and guidance to the businesses and new entrants. The report focuses on the major leaders of the global Neuropathic Pain market along with company profiles, product portfolios, manufacturing and production capacity, financial standings, and global position in the market.

The report on the Global Neuropathic Pain Market analyzes the impact of the COIVD-19 pandemic on the Neuropathic Pain industry. Since its outbreak, the virus-induced illness has spread across the world, compelling the WHO to declare it as a public health emergency. Moreover, COVID-19 has impacted the market by disrupting the supply chains, production, and demand, and brought about a financial slowdown and uncertainty on the markets. The pandemic is anticipated to affect the Neuropathic Pain industry, and the report gives a rundown of the present and future impact analysis of the pandemic on the market.

Get a Sample of the Report @ https://www.reportsanddata.com/sample-enquiry-form/3603

The report on the Global Neuropathic Pain Market is an investigative study that focuses on the important business aspects such as recent developments, technology advancements, and various products and processes developments. The report is formulated via a thorough primary and secondary research with data insights from industry experts and professionals.

The report further studies the major competitors of the Neuropathic Pain market in the industry to provide a comprehensive overview of the competitive landscape. Key factors such as productivity, manufacturing and production capacity, demand and supply ratio, among others, are also discussed in the report. The key companies profiled in the report are Eli Lily and Company, Pfizer Inc., Johnson & Johnson Services Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb and Company, Sanofi SA, Baxter Healthcare Corporation, and Biogen Idec Inc. . Moreover, the report also analyses the key business initiatives undertaken by companies such as mergers and acquisitions, joint ventures, collaborations, and partnerships, among others.

To gain a better understanding of the competitive landscape, the report further analyses the companies operating in the key regions. The regional analysis includes examinations of the major geographical regions such as North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. The report covers import/export ratio, supply and demand trends and patterns, production and consumption ratio, revenue generation, gross profit and margin, and other vital factors.

In market segmentation by types of Neuropathic Pain, the report covers-

By Indication (Revenue, USD Million, 2017 - 2027)-Diabetic neuropathy-Chemotherapy-induced neuropathy-Postherpetic neuralgia-Others

By Treatment (Revenue, USD Million, 2017 - 2027)-Medication-Multimodal Therapy

By End User (Revenue, USD Million, 2017 - 2027)-Hospitals-Clinics-Research Organizations

Get Discount on the Report @ https://www.reportsanddata.com/discount-enquiry-form/3603

Objectives of the Report:-Study of the global Neuropathic Pain market size by key regions, types, and applications with reference to historical data (2017-2018) and forecast (2020-2027)-Industrial structure analysis of the Neuropathic Pain market by identification of various sub-segments-Extensive analysis of key market players along with their SWOT analysis-Competitive analysis-Analysis of Neuropathic Pain market based on growth trends, outlook, and contribution to the total growth of the market-Analysis of drivers, constraints, opportunities, challenges, and risks in the global Neuropathic Pain market-Comprehensive analysis of competitive developments such as expansions, agreements, new product launches, and other strategic alliances

In addition to the key segments, the report also offers information about different aspects that can assist in the progress of the industry. The report covers applicable sales strategies, research and development advancements, online and offline trends, latest product launches and brand promotions, and strategic business expansions. Statistical information about the market is categorized and organized into tables, charts, figures, diagrams, and other graphical presentations.

Access Full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.reportsanddata.com/report-detail/neuropathic-pain-market

Thank you for reading our report. For further query or inquiry, kindly get in touch with us and our team will ensure your requirements for the reports are met.

About Reports and Data:Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

Contact Us:John WHead of Business Development40 Wall St. 28th floor New York CityNY 10005 United StatesDirect Line: +1-212-710-1370

Related Report:1.Frozen Food Market Analysis 2.Plastic Fasteners Market Demand3.Dairy Alternatives Market Growth4.Etanercept Market Forecast5.Electrocardiograph Market Share6.Anti-Snoring Devices And Snoring Surgery Market Size

For more information on this press release visit: http://www.sbwire.com/press-releases/neuropathic-pain-market-overview-size-share-global-industry-outlook-and-statistics-segmentation-and-forecast-to-2027-pfizer-johnson-johnson-services-1326239.htm

See original here:
Neuropathic Pain Market Overview, Size, Share : Global Industry Outlook and Statistics, Segmentation and Forecast to 2027 : Pfizer , Johnson &...

GenSight Biologics Lumevoq (lenadogene neparvovec) drew expert caution about its approval prospects in Lebers hereditary optic neuropathy (LHON) based on nebulousdata from the first two of three Phase III trials. Results from two late-stage trials showed the gene therapy had an effect on the sham eye, and so data from an ongoing third Phase III is needed to clarify efficacy information gaps, experts said.

Data from the RESCUE and REVERSE Phase III trials show patients sham eye also improved, thus diluting efficacy data in the treated eye, experts said. Since the gene therapy also had an impact on the sham eye, questions have been raised about whetherLumevoqs mechanism is fully understood, some noted.

Nevertheless, the level of visual improvement seen in RESCUE and REVERSE is strong enough to draw optimism about the ongoing Phase III REFLECT, as REFLECTs design is intended to clarify the issue, they added. REFLECT is treating both or one eye instead of using a sham injection. Topline REFLECT data is expected in 2Q, with results to be part of its FDA approval filing in 2H.

In its September 2020 EMA filing, GenSight submitted results from RESCUE and REVERSE versus natural history data from LHON patients in other trials, with a decision expected in 4Q. However, experts said it is best to wait for REFLECT results rather than to use natural history data to clarify efficacy issues. The use of natural history data as a benchmark may be confounded by Lumevoq having incompatible patient profiles with RESCUE and REVERSE patients, they said. Natural history data may also include patients receiving prior treatments, which would dilute the datas value as an efficacy benchmark, they added.

GenSight, which has a $282.86m market cap, declined a request for comment.

The function of the 90-patient REFLECT is to clarify data from RESCUE and REVERSE, which showed the sham eye also experienced improvements, said REFLECT investigator Dr Piero Barboni, consultant ophthalmologist, University of Bologna, Italy. While bilateral improvement is possible, localised treatment is assumed to not transfer into the sham eye, added REFLECT investigator Dr Prem Subramanian, professor of ophthalmology, University of Colorado, Denver.

Both the 39-patient RESCUE and 37-patient REVERSE did not meet the primary endpoint of a 15-letter difference or higher in visual acuity for treated eyes compared to sham-treated eyes at 48 weeks. RESCUE patients treated eye experienced a mean improvement of 13 additional letters over baseline versus 11 additional letters in the sham-treated eye, according to a February 2019 press release. In REVERSE, patients treated eye improved by 15 or more letters, compared with 13 or more for the sham-treated eye, as per a 10 December 2020 press release.

Gene therapy studies in animal models show sham eye improvement may becaused by the treatment moving back up the optic nerve and into the untreated eye, explained Alan Boyd, CEO of his eponymous healthcare regulatory consulting firm in Crewe, UK. However, if any trial is designed to use the patients other eye as a control, then there should be no systemic effect, noted Janet Wittes, president, Statistics Collaborative, Washington, DC. There should be stronger understanding of the therapys mechanism, she added. Lumevoq features a recombinant adenoassociated viral vector containing the wild-type ND4 gene. This gene rescues retinal ganglion cells from LHON-induced apoptosis.

With an effect seen in the sham eye, REFLECT needs to demonstrate how both eyes improve when only one is treated, said Subramanian and Barboni. It also needs to show whether it is effective in patients who have lost or are close to losing vision, Subramanian added. REFLECT does not have asham injection, but injects one or both eyes. It is recruiting patients with LHON due to mutations of the ND4 gene, with vision loss present up to one year.

GlobalData's TMT Themes 2021 Report tells you everything you need to know about disruptive tech themes and which companies are best placed to help you digitally transform your business.

Although RESCUE and REVERSE did not meet their primary endpoints, other data from these trials show the promise of the gene therapys clinical value, which is reassuring for REFLECTs success prospects, added Subramanian. For example, in REVERSEs primary endpoint, 81% of 37 patients experienced clinically relevant recovery in the treated eye, defined as a 10-letter improvement or higher in the Early Treatment Diabetic Retinopathy Study (EDTRS) Visual Acuityscore, according to the aforementioned December 2020 release.

Given the level of the treated eyes visual recovery reported in RESCUE and REVERSE, it is difficult to argue visual improvement was down to the natural history of the condition and not without the gene therapys impact, said Dr Byron Lam, professor of Ophthalmology, University of Miami, Florida. Based on the natural progression of the disease, patients do not typically recover to the same extent as patients in RESCUE and REVERSE, he explained, adding REFLECT, by removing the sham injection, will underscore the gene therapys efficacy.

RESCUE and REVERSEs data may be strong enough for FDA approval, Boyd said. He pointed to Roches Luxturna (voretigene neparvovec), which was approved in 2017 for biallelic RPE65 mutation-associated retinal dystrophy. While its Phase III(NCT00999609) data did not have a control group, it did not reduce its approval prospects, he added. Data from the first two Phase III Lumevoq trials may be enough for conditional EMA approval, and REFLECT data may lead to full EMA approval, added Boyd.

However, other experts were more sceptical of the gene therapys overall approval prospects based on available RESCUE and REVERSE data alone, noting the improvement in the control eye undermined the validity of both trials results. As such, REFLECT results are needed to fill in the data information gaps, they added.

In its application to the EMA, GenSight filed data combining RESCUE, REVERSE and their long-term trials (NCT03406104) results versus natural history data. Natural history data were gathered from a variety of sources, such as LHON natural history studies andGenSights Phase III REALITY trials (NCT03295071) natural history registry. The comparison shows a statistically significant (p<0.01)and clinically meaningful difference with Lumevoq in visual outcomes by month 48, according to a 21 September 2020 press release.

Still, it is not standard to use natural history data from other studies as an efficacy benchmark, noted William Feuer, biostatistician, University of Miami, Florida. There are limitations to natural history data, such as how it does not capture everyone with the disease but only those who seek medical attention, Subramanian said. How often patients chose to return for examination can confuse the natural history datas value as a benchmark, he added.

Another factor obscuring the natural history data is patients who use prior treatment may have been included in this data pool, experts said. In RESCUE and REVERSE, patients were excluded if they had not completely discontinued using Takeda Pharmaceuticals Raxone (idebenone) at least seven days prior to the second visit. Ideally, clarity is needed about how natural history data being used for comparison would exclude patients previously treated with Raxone, said Subramanian. There needs to be a distinction between natural history data and treated history, said Wittes, adding natural history is what would happen to the disease if there were no treatment whatsoever.

In the pooled data from RESCUE and REVERSE, both treated and sham eyes are referred to as treated eyes. While it is highly unusual for an analysis to include what was previously a control eye in its analysis of treated eyes, this may be beneficial as it serves to understate the therapeutic effect of the gene therapy, experts agreed. In including sham eye data showing improvements, GenSight is reducing the treatment effect, making a more conservative estimate of the gene therapys therapeutic impact, agreed Wittes and Feuer.

Sean Rai-Roche is a Reporter for Clinical Trials Arena parent company GlobalDatas investigative journalism team. A version of this article originally appeared on the Insights module of GlobalDatas Pharmaceutical Intelligence Center. To access more articles like this, visitGlobalData.

Drug Processing Technology and Laboratory Equipment

28 Aug 2020

AI Drug Discovery and Development Company

28 Aug 2020

Software, Consulting and Workshops for Data Analysis and Model-Based Decision Support

28 Aug 2020

Original post:
Approval of GenSight's gene therapy based on existing Phase III results - Clinical Trials Arena

This contemporary, modern market research compilation is a systematic overview of the overall market status and structure prevalent in global Chemotherapy Induced Peripheral Neuropathy Treatment market and their rampant implications upon holistic growth trajectory and further probabilities in the near future. The report is based on extensive primary and secondary research initiatives and the insights thus achieved have been stacked systematically aided by several graphs, tables and charts to encourage seamless comprehension. The report sheds ample light into both past and current developments to infer futuristic probabilities. Relevant understanding on market prognosis, trends, policy updates and current development statistics have all been highlighted in thorough detail for quick deductions and subsequent investment discretion by Orbis Pharma Reports.

Get sample copy of [emailprotected] https://www.orbispharmareports.com/sample-request/90918

Major Company Profiles operating in the Chemotherapy Induced Peripheral Neuropathy Treatment Market:

AptinyxMetys PharmaceuticalsKrenitsky PharmaceuticalsKinetaRegenacy PharmaceuticalsWinSanTorPeriphaGenSova PharmaceuticalsMAKScientificDermaXonSolasia PharmaAsahi Kasei PharmaNemus BioscienceImmune PharmaceuticalsApexian PharmaPledPharmaMajor Types CoveredCalcium Channel ?2-delta LigandsAntidepressantsOpioidsOthers

By the product type, the market is primarily split into

Calcium Channel ?2-delta LigandsAntidepressantsOpioidsOthers

By the application, this report covers the following segments

Platinum AgentsTaxanesVinca AlkaloidsOthers

Browse the complete report @ https://www.orbispharmareports.com/2015-2027-global-chemotherapy-induced-peripheral-neuropathy-treatment-industry-market-research-report-segment-by-player-type-application-marketing-channel-and-region/

Regional Overview:This versatile research report presentation on global Chemotherapy Induced Peripheral Neuropathy Treatment market, presented by Orbis Pharma Reports has maintained highest parameters of research practices to unravel crucial details. Holistic geographical diversifications have been carefully analyzed and prominent growth centers have been categorically flagged to maintain uniform growth trends.Besides entailing region-specific details, country-wise detailing have also been included to encourage rapid decision making. For maximum reader discretion and subsequent investment decisions, this report on global Chemotherapy Induced Peripheral Neuropathy Treatment market as assessed by Orbis Pharma Reports reveals Germany, France, Italy, UK as ideal growth hotspots, followed by American growth hubs such as Mexico, Brazil, US and Canada. MEA countries and APAC nations have also been thoroughly scanned to understand growth patterns, competition intensity as well as vendor activities across these growth points.

For Any Query on the Chemotherapy Induced Peripheral Neuropathy Treatment Market: https://www.orbispharmareports.com/enquiry-before-buying/90918

Decoding Segment Specifications:The report by Orbis Pharma Reports on global Chemotherapy Induced Peripheral Neuropathy Treatment market encourages complete stratification of the market in terms of segments to understand growth patterns. All prominent segments highlighted in the report have been assessed based on set parameters such as capital diversion, inventory management as well as utility diversification, besides exploring supply chain developments to understand segment potential in growth progression. Each of the segment identified has been assessed on the basis of various market parameters to explore growth projections and likelihood. The report is based on complete SWOT and PESTEL assessment, followed by PORTERs Five Forces assessment and evaluation of all DROT factors. These details are highly crucial to encourage appropriate investment decisions on the part of inquisitive readers and aspirational investors.Orbis Pharma Reports also sketches the prevalent competition landscape, isolating frontline players as well as their growth proficient business decisions. Based on these business decisions, this report helps investors to deliver lucrative business decisions.

About Us :

At Orbispharma we curate the most relevant news stories, features, analysis and research reports on the important challenges undertaken by the pharmaceutical and related sectors. Our editorial philosophy is to bring you sharp, focused and informed perspective of industries, the end users and application of all upcoming trends into the pharma sector. Orbispharma believes in conversations that can bring a change in one of the most crucial economic sectors in the world. With these conversations we wish our customers to make sound business decisions with right business intelligence.

Contact Us :

See more here:
Chemotherapy Induced Peripheral Neuropathy Treatment Industry Market 2021 by Company, Regions, Type and Application, Forecast to 2027:Aptinyx, Metys...

Avail a detailed research offering a comprehensive analysis of the developments, growth outlook, driving factors, and key players of the Chemotherapy Induced Peripheral Neuropathy Treatment market in the latest research report added by Research N Reports. The recent research report on the global Chemotherapy Induced Peripheral Neuropathy Treatment Market presents the latest industry data and future trends, allowing you to recognize the products and end users driving Revenue growth and profitability of the market.

Request a Sample@ https://www.researchnreports.com/request_sample.php?id=252343

Abbott, Bristol Myers Squibb, Cipla Limited, Eli Lilly and Company, GlaxoSmithKline plc., Lupin Limited, Merck and Co. Inc., Novartis AG, Pfizer Inc., Dr. Reddys Laboratories, Mylan NV, Johnson & Johnson Services Inc., and Teva Pharmaceutical Industries Ltd. among others.

The report offers an extensive analysis of key drivers, leading market players, key segments, and regions. Besides this, the experts have deeply studied different geographical areas and presented a competitive scenario to assist new entrants, leading Chemotherapy Induced Peripheral Neuropathy Treatment players, and investors determine emerging economies. These insights offered in the report would benefit market players to formulate strategies for the future and gain a strong position in the global market.

(The sample of this report is readily available on request).

This Free report sample includes:

Brief introduction to the research report.

Graphical introduction of regional analysis.

Top players in the Chemotherapy Induced Peripheral Neuropathy Treatment with their revenue analysis.

Selected illustrations of market insights and trends.

Example pages from the report.

Ask for Discount@ https://www.researchnreports.com/ask_for_discount.php?id=252343

Research methodology.

The report begins with a brief introduction and Chemotherapy Induced Peripheral Neuropathy Treatment overview of the Chemotherapy Induced Peripheral Neuropathy Treatment industry followed by its market scope and size. Next, the report provides an overview of market segmentation such as type, application, and region. The drivers, limitations, and opportunities for the market are also listed, along with current trends and policies in the industry.

The report provides a detailed study of the growth rate of every segment with the help of charts and tables. Furthermore, various regions related to the growth of the Chemotherapy Induced Peripheral Neuropathy Treatment are analyzed in the report.

These regions include:

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Besides this, the research demonstrates the growth trends and upcoming opportunities in every region.

Inquire before Buying@ https://www.researchnreports.com/enquiry_before_buying.php?id=252343

Analysts have revealed that the Chemotherapy Induced Peripheral Neuropathy Treatment market has shown several significant developments over the past few years. The report offers sound predictions on market value and volume that can be beneficial for the market players, investors, stakeholders, and new entrants to gain detailed insights and obtain a leading position in the market.

Additionally, the report offers an in-depth analysis of key market players functioning in the global Chemotherapy Induced Peripheral Neuropathy Treatment industry.

The research presents the performance of each player active in the global Chemotherapy Induced Peripheral Neuropathy Treatment market. It also offers a summary and highlights the current advancements of each player in the market. This piece of data is a great source of study material for the investors and stakeholders interested in the market. In addition, the report offers insights on suppliers, buyers, and merchants in the market. Along with this, a comprehensive analysis of consumption, market share, and growth rate of each application is offered for the historic period.

Company Overview :

Our Research Will Change The Way You Think About Problems. We Provide Global Consulting That Can Transform Businesses And Give You An Experience Of Innovative Solutions And Outcomes. Research N Reports Helps Clients Harness The Power Of Innovation To Thrive On Change. We Have Successfully Guided Businesses Throughout The World With Our Market Research Reports. We Are Uniquely Positioned To Lead Digital Transformations, Thus Creating Greater Value For Clients By Presenting Growth Opportunities In The Global Market. Our Profound Experience Provides A Clear And Confident Vision To Help Clients Navigate The Future. Research N Reports Techniques Encompasses Both Qualitative And Quantitative Modes To Provide Customized And Highly Flexible Tailored Research Studies So That You Get Information That Is Just The Best-Fit To Make Informed Strategic Organizational Decisions. Research N Reports Helps Clients Decode The Future To Be More Successful And Innovative.

Contact Us:

Address: 10916 Gold Point Dr

Houston, TX 77064, USA

USA : +1 510-402-1213

UK : +44 753-712-1342

APAC & Malta : +356 2792 2019

sales@researchnreports.com

Excerpt from:
Big Boom in Chemotherapy Induced Peripheral Neuropathy Treatment market with key market players growing at a good CAGR Year on year with increasing...

Reaching the revenues of over US$ 6 Bn at the end of 2019, the globalneuropathic pain management marketis projected for a healthy CAGR during the forecast period (2019 2029). Increasing prevalence of neuropathic pain disorders and growing awareness about pain medication are boosting the demand for pain management drugs.

Pipeline strategies by manufacturers are focused on introducing advanced drugs with minimum side effects to increase market share. For instance, Pfizer sponsored drug Pregabalin, effective in treating neuropathic (nerve) pain resulting from peripheral nerve trauma that is in phase 3 clinical trials. Increasing research and development activities to develop medications for indications such as post-herpetic neuralgia are creating significant opportunities for manufactures to flourish in the market.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/4149

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/4149

Key Takeaways Neuropathic Pain Management Market Study

Increasing prevalence of diabetic neuropathy and availability of approved neuropathy pain medications have significantly added to the opportunities for market growth, thereby fostering the rate of adoption of neuropathic pain management drugs.

Increasing R&D Spending by Pharmaceuticals Companies Shaping Future

One of the key factors observed to impact the neuropathic pain management market growth is the development of new drugs for treatment of neuropathic and chronic pains. Companies are focusing on clinical trials to develop drugs for efficient treatment of neuropathic pain. For instance, Eli Lilly and Company developed Duloxetine (LY248686) for Diabetic Peripheral Neuropathic Pain (DPNP) that is under phase 4 clinical trial.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/4149

At the same time, companies are focused on expanding therapeutic applications of drugs such as opioids and steroids for neuropathic pain management without causing any serious side effects to patients. Currently, more than 100 clinical trials are been carried out for pain management. Among those clinical trials, nearly half of the clinical trials are for various indications of neuropathic pain such as diabetic neuropathy and post-herpetic neuralgia.

What Does the Report Cover?

The neuropathic pain management market, a new study from Persistence Market Research, provides unparalleled insights on evolution of the neuropathic pain management market during 2014 2018 and presents demand projections during 2019 2029 on the basis of drug class (tricyclic anti-depressants, anticonvulsants, SNRIs, capsaicin cream, local anesthesia, opioids, steroids, and others), indication (diabetic neuropathy, trigeminal neuralgia, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy and others), distribution channel (retail pharmacies, hospital pharmacies, and online pharmacies) across prominent regions (North America, Latin America, Europe, Asia Pacific and MEA).

Explore Extensive Coverage of Persistence Market Research Life Sciences & Transformational Health Landscape

About Us :-

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers experience by acting as the missing link between customer relationships and business outcomes. The best possible returns are assured therein.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Website https://www.persistencemarketresearch.com

https://farmingsector.co.uk/

See the article here:
The Neuropathic Pain Market To Move Away From Insipidness, Reach US$ 10414.0 Million - Farming Sector

Ischemic optic neuropathy is caused due to a small vessel infraction of the optic nerve and is a major cause of blindness or impaired vision among the inflicted. There are two types of ischemic optic neuropathies viz. anterior ischemic optic neuropathy and posterior or non-anterior ischemic optic neuropathy. Anterior ischemic optic neuropathy is caused by the inflammation of arteries supplying blood to the optic nerve whereas posterior or non-anterior ischemic optic neuropathy is caused due to reasons other than inflammation of the arteries. Anterior ischemic optic neuropathy is more prevalent as compared to posterior ischemic optic neuropathy. In anterior ischemic optic neuropathy, immediate treatment is required to prevent vision loss in the fellow eye as approximately 50 percent of cases have chances of blindness in another eye within a span of 5 to 10 days without treatment. The symptoms of ischemic optic neuropathy include unilateral, acute and painless visual loss for hours to days. Hypertension, diabetes, and hypercholesterolemia are some of the well-known risk factors associated with ischemic optic neuropathy disease. Other factors include generalized hypoperfusion, sleep apnea, nocturnal hypotension, vasospasm, severe anemia and failure of autoregulation.

To remain ahead of your competitors, request for a sample [emailprotected]https://www.persistencemarketresearch.com/samples/23077

Technological advancements in ischemic optic neuropathy treatment and availability of alternative drugs are anticipated boost the demand for ischemic optic neuropathy treatments over the forecast period.

The global ischemic optic neuropathy treatment market can be segmented on the basis of disease type, treatment type and end user.

On the basis of disease type, the global ischemic optic neuropathy treatment market can be segmented into:

On the basis of treatment type, the global ischemic optic neuropathy treatment market can be segmented into:

On the basis of end user, the global ischemic optic neuropathy treatment market can be segmented into:

To receive Methodology request here@https://www.persistencemarketresearch.com/methodology/23077

The global ischemic optic neuropathy treatment market is expected to register a significant CAGR over the forecast period. The increasing adoption of recently approved intravitreal implants in the treatment of ophthalmology diseases is anticipated to propel the growth of the ischemic optic neuropathy treatment market over the forecast period. Leading pharmaceutical and drug manufacturing companies from developed countries are substantially investing in R&D, infrastructure and new technologies in ophthalmology therapeutics to capture a market share in the growing burden of eye diseases, which also boosts the growth of the global ischemic optic neuropathy treatment market. With growing awareness towards eye-related complications that lead to blindness, geriatric population and diabetic patients in developed countries, such as the U.S., Russia, and Poland, Germany and Japan are seen to have a proactive approach for treatment related to complications rather than reactive treatment, which also bolsters the growth of the market of ischemic optic neuropathy treatment.

Corticosteroid is the first choice of therapy for patients with ischemic optic neuropathy in prominent countries, such as the U.S., Germany, France, and Russia; however, a majority of patients have developed resistance to anti-VEGF, which leads to the adoption of alternative therapy in patients with ischemic optic neuropathy. This is anticipated to drive the growth of the global ischemic optic neuropathy treatment market in the long run.

To receive extensive list of important regions, Request TOC here @https://www.persistencemarketresearch.com/toc/23077

However, medications such as intravitreal injections of anti-VEGF drugs and corticosteroids lead to an instant increase in intraocular pressure, which may lead to severe adverse effects such as conjunctival haemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased and vitreous detachment. This may restrain the growth of the global ischemic optic neuropathy treatment market.

On the basis of regional presence, the global ischemic optic neuropathy treatment market can segmented into five key regions, namely North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa.

North America is a dominant region in the market and contributes a leading share to the global ischemic optic neuropathy treatment market in terms of revenue. The market in the region is expected to register significant growth over the forecast period due to the availability of developed medical infrastructure and treatment facilities in the region. Europe also contributes a moderate share and registered a healthy growth rate in the global ischemic optic neuropathy treatment market. The APEJ region has become a lucrative market for ischemic optic neuropathy treatment and is anticipated to register a significant share over the forecast period, due to the increase in research and development activities along with the growth in medical tourism in the region. Latin America and MEA are in the nascent stage in the global ischemic optic neuropathy treatment market and are expected to register moderate growth over the forecast period.

Some of the market players operating in the ischemic optic neuropathy treatment market include

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

https://mmcthemonitor.com/

Originally posted here:
The Ischemic Optic Neuropathy Treatment Market to grow superlatively in the next 10 years - The Monitor

In the early days of the pandemic, we believed that once an individual initially recovered from a COVID-19 infection, the worst was over. However, over the last many months, researchers, doctors, and health experts realized that for some people, the most crippling manifestations of the coronavirus occur after the initial infection has passed. Post-COVID Syndrome, "Long Hauler's Syndrome, or long-term COVID are the names given to a mysterious condition that can occur many months after 'recovering' from COVID-19," William Li, MD, physician, scientist and author of the New York Times bestseller Eat to Beat Disease: The New Science of How Your Body Can Heal Itself tells Eat This, Not That! Health. Read on to see if you have the symptomsand to ensure your health and the health of others, don't miss these Sure Signs You've Already Had Coronavirus.

Although Post-COVID Syndrome has been identified, we are still struggling to understand all the hows, whys, and whens. "While this syndrome is still not well understood, what is clear is that the condition involves damage to blood vessels, inflammation, and damage to nerves, known as neuropathy."

One of the most perplexing aspects of long haulers is that many of them suffered initial infections that were seemingly mild and required zero medical treatment. However, weeks to months later, they struggle to function in everyday life.

One of the more debilitating symptoms of long hauler syndrome is extreme exhaustion. "Many viruses (e.g.mono and dozens of others) can trip a critical almond-sized circuit breaker in the brain called the hypothalamus," says Jacob Teitelbaum, MD, board-certified internist nationally known expert in the fields of chronic fatigue syndrome and author of From Fatigued to Fantastic!. "This leaves people barely or nonfunctional. They may barely be able to work, or even be housebound," explains Dr. Teitelbaum. "The virus can directly suppress the cellular energy furnaces called the mitochondria, leaving you feeling wiped out."

While shortness of breath is one of the more common symptoms of an initial COVID-19 infection, it is also a defining sign of long hauler syndrome. "There's no more infection, but you still have difficulty breathing at times," explains Dr. Lil. "Early studies have revealed blood vessel loss in the lungs as one explanation."

"Many long haulers report irregularities in their heart, including the sensation of their heart racing. The coronavirus can infect the heart and damage its tiniest blood vessels, but some people experience their heart rate suddenly increases," Dr. Li explains.

Dr. Li explains that an increase in heart rate can leave you feeling dizzy and weak. "The cause of this is unknown but may involve both nerves and blood vessels," he says.

RELATED: 7 Tips You Must Follow to Avoid COVID, Say Doctors

Sleep disturbances are also common symptoms of long COVID. "This includes difficulty falling and staying asleep, as well as waking unrefreshed," says Dr. Teitelbaum. "This is because the hypothalamic circuit breaker controls sleep."

Brain fog, a term commonly used by Dr. Anthony Fauci, the nation's leading infectious disease expert, in association with long term COVID, is another mysterious manifestation. Dr. Teitelbaum explains it as having "difficulty with short term memory, as well as word finding or substitution. This occurs for many reasons, including altered brain blood flow from the virus and overactivity of brain cells called microglial activation," he says.

Like shortness of breath, a persistent cough can come from lung or heart inflammation from the virus, claims Dr. Teitelbaum. "This normally heals over time, and recovery can be accelerated with natural therapies," he says.

If you have the "paradoxical combination of exhaustion and insomnia despite being more than 12 weeks after the onset of COVID-19 symptoms," you can assume you are a long hauler. "Called post-viral Chronic Fatigue Syndrome (CFS), this occurs in about 15% of cases," Dr. Teitelbaum says.

RELATED: The New COVID Symptom Every Woman Needs to Know

While antibody tests aren't flawless, and can rear false negatives, in many cases they can detect antibodies of the virus and confirm that you were, in fact, infected. If you believe you are a long hauler, you should contact your physician to discuss treatment options.

As for yourself, follow Fauci's fundamentals and help end this surge, no matter where you livewear a face mask, social distance, avoid large crowds, don't go indoors with people you're not sheltering with (especially in bars), practice good hand hygiene, get vaccinated when it becomes available to you, and to protect your life and the lives of others, don't visit any of these 35 Places You're Most Likely to Catch COVID.

See original here:
Sure Signs You've Already Had COVID, According to Specialists - Eat This, Not That

The CURE Voices program highlights the stories and advice of patients, survivors and caregivers alike who have valuable knowledge and experience with cancer. It is also sometimes an outlet to discuss the challenges of cancer that may get lost in the headlines of the latest approval or just provide a space of understanding.

In 2020, just like everyone else, the contributors had to deal with an ever-changing world while simultaneously dealing with the ongoing challenges of cancer even after treatment is well over. Here are the 10 most popular Voices articles from 2020 for you to revisit.

10. COVID-19 is Stealing Precious Time from Cancer Survivors

In the summer, contributor Jane Biehl wrote about how the changes the COVID-19 pandemic brought about to our daily lives was robbing cancer survivors and patients alike of the precious borrowed time they had. I feel cheated. I think if we are honest, we all do. Precious time, which we cancer survivors know is fleeting, is flying by and we all feel robbed.

9. The Elephant in the Room: Cancer Treatment Made Me Clumsier

Felicia Mitchell discusses the lingering ramifications of her treatment for cancer and how she had to find a balance in dealing with her neuropathy and living the life she wanted to at home. For a long time, I refused to acknowledge the lingering effects of neuropathy. I found a way to joke about it and told everybody I was clumsy. To acknowledge the elephant in the room, I had to admit I needed to explore balance further, she writes.

8. Old Photos Give Cancer Survivors Snapshots of Their Former Selves

We can never predict our future of course, but looking back, there will always be snapshots of our former selves. One of the keys for me in accepting my disease as something more than simply an unfair curse was in seeing those snapshots of me before I had cancer as a separate life in a sense, writes male breast cancer survivor Khevin Barnes as he explores his old life with his new reality.

7. Clearing Away Clutter and the Fear of Another Cancer

Recurrence is a thought never far away from the mind of anyone who has been touched by cancer. Write Laura Yeager discusses that fear as she looks to declutter both her house and her own fears.

6. The Big Dates After Cancer Takes A Loved One Away

After cancer took her husband away, caregiver Erica Finamore discusses the importance of celebrating the important dates and milestones. Even after cancer has taken your loved one away.

5. Becoming The Supporter Over The Cancer Survivor

Sometimes the cancer survivor finds themselves in the position of supporter, such as the case of contributor Danielle Ripley-Burgess who had to help her friend through a breast cancer diagnosis. Ive learned what being a good friend to a cancer survivor takes. And this month, it looks like making sure other breast cancer survivors, get their time to shine.

4. Dont Ignore Sleep Problems That Come From Cancer Treatment

Cancer, and subsequent treatments for cancer, come with a host of side effects and lingering issues that stay with you for the rest of your life, but that doesnt mean you cant mitigate them. Contributor Martha Carlson discusses why you shouldnt ignore sleep issues that come from treatment, and some tips on how to counteract them.

3. Triggers That Remind Me of My Daughter's Cancer Are Everywhere

A cancer diagnosis is a traumatic event for everyone involved, and as with most traumatic events, there are things big and small that pull us back into the distress as if it was happening right now, writes contributor Debbie Legault as she navigates the lingering emotions from her own daughters cancer journey.

2. Weighing The Pros and Cons of Receiving the COVID-19 Vaccine

Given the opportunity to receive the COVID-19 vaccine as a first responder, contributor Tamera Anderson-Hana weighs the pros and cons of receiving the vaccine and trying to find a way past COVID-19.

1. A Final Farewell

After the passing of CURE Magazine co-founder and longtime contributor Kathy LaTour contributor Kim Johnson writes about her brief interactions with Kathy LaTour and how her writing shaped her own.

Read more:
The 10 Most Popular CURE Voices Articles of 2020 - Curetoday.com

Survey responses revealed the physical and emotional toll of primary hyperoxaluria (PH) on patients and their families,1 while an accompanying paper aimed to identify appropriate end points for clinical trials of treatments.2

Both papers were published in the Clinical Journal of the American Society of Nephrology, and they highlight areas of need for individuals with PH, a rare genetic condition that causes the body to produce excess oxalate, leading to kidney stones, kidney failure, and oxalosis (oxalate accumulation).

Among the 42 survey respondents (17 patients, 25 parents/caregivers), 60% of the patients had PH type 1 (the most severe form), half were 17 years or younger, and 24% had experienced dialysis. Kidney stones were a top concern for patients and parents. The stones commonly occur in childhood in those with PH and can recur unpredictably throughout the lifespan, sometimes requiring surgical procedures.

My son has had multiple surgical procedures beginning at 6 months old. These procedures were very traumatic both physically and emotionally, a parent reported.

Another common theme was anxiety around the prospect of kidney failure, which can lead to oxalosis. Dialysis is initiated early in PH, but it is not completely effective in clearing the oxalate load, meaning that patients may require hemodialysis 6 days per week plus peritoneal dialysis daily. Frequent dialysis can be a great burden on caregivers, with some survey respondents describing the lack of sleep they experienced while coordinating their childrens routines.

Oxalosis was a prominent fear among the respondents; systemic oxalosis can be associated with bone fractures, anemia, joint damage, vision impairment, and neuropathy.

My brother experienced such intense nerve pain that he was unable to wear gloves during the winter. I ordered special gloves made of light but warm material for him. Unfortunately, he died before they were delivered, a respondent recounted.

Survey respondents also expressed the psychological toll that comes from living with PH and not knowing when kidney failure may occur. The authors noted that missing work for health reasons can cause significant medical and financial burdens.

Due to the many stressors from living with PH, the survey respondents agreed that new therapies to prevent oxalosis and avoid dialysis and transplant are of utmost importance.

In the accompanying article about end points of clinical trials for PH treatments, the authors note that there are no therapies approved by the FDA. The project reported in the study convened a work group of patients, physicians, investigators, industry representatives, and regulators to discuss the clinical outcomes and end points that could be used to evaluate new treatments. They concluded that the strongest candidates were kidney stone occurrence, change in the estimated glomerular filtration rate, urine oxalate, and plasma oxalate.

The article also detailed the advantages and disadvantages of using each potential end point. For instance, kidney stones have a significant impact on quality of life and functioning for patients with PH, but there are varying standards for measurement and longitudinal monitoring of the stones. Conversely, kidney failure is an outcome that is easy to measure, but it may not occur frequently enough in a trial that it could be evaluated as an outcome, depending on the length and sample size of the trial.

The authors noted that their conclusions on the feasibility of each potential are based mainly on patients with PH type 1, who account for most patients with PH. Small numbers of patients with [PH] type 2 and [PH] type 3 in [PH] registries do not yet provide a similar strength of evidence for these biomarkers in other forms of [PH], they explained.

References

1. Lawrence JE, Wattenberg DJ. Primary hyperoxaluria: the patient and caregiver perspective. Clin J Am Soc Nephrol. 2020;15(7):909-911. doi:10.2215/CJN.13831119

2. Milliner DS, McGregor TL, Thompson A, et al. End points for clinical trials in primary hyperoxaluria. Clin J Am Soc Nephrol. 2020;15(7):1056-1065. doi:10.2215/CJN.13821119

Read this article:
Patients, Caregivers Report Burden of Living With Primary Hyperoxaluria - AJMC.com Managed Markets Network

Imagine experiencing burning, tingling, and numbness in your legs day in and day out, getting worse over time and your doctors cant find a reason for it.

Thats the situation for millions of people who suffer from idiopathic sensory polyneuropathy. The term idiopathic means that no cause can be identified; sensory refers to the type of nerve, in this case those carrying nerve signals such as pain or temperature; poly means many and neuropathy means nerve disease. So, this is a condition of unknown cause that damages multiple nerves; the most affected nerves tend to be those that provide sensation to the legs and feet.

Sometimes other terms are used, including cryptogenic neuropathy or chronic polyneuropathy of undetermined cause. For some people, neuropathy is due to diabetes, alcohol abuse, medications, or other conditions. But in nearly half of all cases, sensory polyneuropathy is idiopathic.

Regardless of which name is used, the condition is frustrating, annoying, and sometimes debilitating. And without an identifiable and reversible cause, there is no cure. While a number of medications are commonly prescribed, its not clear which is most effective or safest. So, doctors generally recommend a period of trial and error. One medication after another is prescribed, until one is found that is effective and doesnt cause intolerable side effects.

Unfortunately, it can take many months or even longer to find a treatment that works. Doctors have little guidance to know which ones to start with. Thats why research comparing treatment options is so important and yet, precious little comparative research on treatments for idiopathic sensory polyneuropathy has been published.

Researchers publishing in JAMA Neurology describe the results of a unique trial in which 402 people with idiopathic sensory polyneuropathy were randomly assigned to one of four medications: duloxetine, mexiletine, nortriptyline, or pregabalin. After 12 weeks, each person rated their neuropathy symptoms on a scale from 1 to 10, noted any side effects, and reported whether they had quit taking the medication due to side effects, cost, or some other reason.

Though the trial is important and much needed, the results were disappointing.

This trial had a number of important limitations:

Direct comparisons of treatments for idiopathic sensory polyneuropathy which many simply call neuropathy are sorely needed, so this trial is important. Yet, the biggest take-home message of this research is that many current treatments arent very good.

Overall, nortriptyline and duloxetine appeared to outperform the other drugs in this trial, so they would be good choices to start with rather than pregabalin and mexiletine. But when the best treatments work well for only a quarter or less of patients, and nearly half quit treatment in the first 12 weeks, its clear that better, safer, and less expensive treatments are needed.

Perhaps we already have better treatments that werent part of this trial. Well need additional comparative research to know for sure.

Follow me on Twitter @RobShmerling

Go here to read the rest:
Treating neuropathy: Which medication is best? - Harvard Health Blog - Harvard Health

Stop the debilitating symptoms of neuropathy with help from Advanced Nerve and Health Center

HOUSTON Call Advanced Nerve and Health Center now at 832-626-1260 or log on to NerveAndHealth.com.

The Advanced Nerve and Health Center has a limited time offer for Great Day Houston viewers. For $29, get a tele-health visit, an in-office consultation, a copy of Dr. Thai's "Healthy Diet to Heal Nerve Pain" book, and a diagnostic nerve test to see if they can help. This is a $249 value.

Advanced Nerve and Health Center is located at 8558 Katy Freeway, Suite 116, Houston, TX 77024.

The Advanced Nerve and Health Center treats the root cause of neuropathy and reverses the damage to the nerve. Dr. Bao Thai and Dr. Aliena Sohail shared more in the video above about their process and how it works. Patient Charlotte Leach-Kiel used to be in such extreme pain that it would wake her up at night. She said it felt like her body was being tasered. She knew she had to reach out to Advanced Nerve & Health Center so she could have a better quality of life. After treatments, she has seen improvement, feels so much better, and no longer wakes up in the middle of the night.

This content sponsored by Advanced Nerve and Health Center.

See original here:
Take your life back from the pain of neuropathy - KHOU.com

The Global Chemotherapy Induced Peripheral Neuropathy Treatment Market analysis report published on IndustryGrowthInsights.com is a detailed study of market size, share and dynamics covered in XX pages and is an illustrative sample demonstrating market trends. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It covers the entire market with an in-depth study on revenue growth and profitability. The report also delivers on key players along with strategic standpoint pertaining to price and promotion.

Get FREE Exclusive PDF Sample Copy of This Report: https://industrygrowthinsights.com/request-sample/?reportId=171696

The Global Chemotherapy Induced Peripheral Neuropathy Treatment Market report entails a comprehensive database on future market estimation based on historical data analysis. It enables the clients with quantified data for current market perusal. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and regional analysis. Listed out are key players, major collaborations, merger & acquisitions along with upcoming and trending innovation. Business policies are reviewed from the techno-commercial perspective demonstrating better results. The report contains granular information & analysis pertaining to the Global Chemotherapy Induced Peripheral Neuropathy Treatment Market size, share, growth, trends, segment and forecasts from 2020-2026.

With an all-round approach for data accumulation, the market scenarios comprise major players, cost and pricing operating in the specific geography/ies. Statistical surveying used are SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics. Graphs are clearly used to support the data format for clear understanding of facts and figures.

Customize Report and Inquiry for The Chemotherapy Induced Peripheral Neuropathy Treatment Market Report: https://industrygrowthinsights.com/enquiry-before-buying/?reportId=171696

Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Primary research, interviews, news sources and information booths have made the report precise having valuable data. Secondary research techniques add more in clear and concise understanding with regards to placing of data in the report.

The report segments the Global Chemotherapy Induced Peripheral Neuropathy Treatment Market as:Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size & Share, by Regions

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size & Share, by ProductsCalcium Channel 2-delta LigandsAntidepressantsOpioidsOthers

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size & Share, ApplicationsPlatinum AgentsTaxanesVinca AlkaloidsOthers

Key PlayersAptinyx IncAsahi Kasei Pharma CorpRegenacy PharmaceuticalsMAKScientific LLCMetys Pharmaceuticals AGNemus Bioscience IncPledPharmaSova Pharmaceuticals IncDermaXon LLCImmune Pharmaceuticals IncKineta IncKrenitsky Pharmaceuticals IncPeriphaGenApexian PharmaWinSanTorSolasia Pharma K.K.

Avail the Discount on this Report @ https://industrygrowthinsights.com/ask-for-discount/?reportId=171696

IndustryGrowthInsights offers attractive discounts on customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About IndustryGrowthInsights:INDUSTRYGROWTHINSIGHTS has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario, CA 91764, United States.Phone No: USA: +1 909 545 6473Email: [emailprotected]Website: https://IndustryGrowthInsights.com

Read more here:
Chemotherapy Induced Peripheral Neuropathy Treatment Market Global Growth, Opportunities, Industry Analysis & Forecast To 2027 - Murphy's Hockey...

DataIntelo, a prominent market research firm, has published a detailed report on Global Neuropathy Pain Treatment Market. This market research report provides comprehensive and in-depth analysis on the market which can possibly help an enterprise to identify lucrative opportunities and assist them with fabricating creative business strategies. The market report provides information about the current market scenario regarding the global supply and demand, key market trends and opportunities in the market, and challenges and threats faced by the industry players.

The Neuropathy Pain Treatment market report talks about the competitive scenario among the industry players and imparts aspiring and emerging industry players with the future market insights in a detailed manner. This market report includes crucial data and figures which are structured out in a concise yet understandable manner. The research report covers the updates on the government regulations and policies which illustrates key opportunities and challenges of the market. DataIntelo has been monitoring the market since few years and collaborated with eminent players of the industry to give better insights on the market. It has conducted vigorous research and implied robust methodology to provide accurate predictions about the market.

You can buy the complete report on @ https://dataintelo.com/checkout/?reportId=43829

Impacts of Advancements and COVID-19 on the market.

Amidst the COVID-19, few segments of the market have witnessed a disruption due to the gap in supply and demand which has impacted the growth of the Neuropathy Pain Treatment market. Along with this, the latest advancements have changed the market dynamics of the market. This research report covers the wide-range analysis of the COVID-19 impact to the industry and gives out insights on the change in the market scenario due to the advancements.

Request A Free Sample Report @ https://dataintelo.com/request-sample/?reportId=43829

Market Segmentation

Some of the major companies that are covered in the report.

DepomedEli LillyEndo InternationalPfizerAllodynic TherapeuticsArbor Pharmaceuticals

Note: Additional companies

Based on the type, the market is segmented into

Calcium Channel Alpha 2-delta LigandsSerotonin-norepinephrine Reuptake InhibitorsOthers

Based on the application, the market is segregated into

Retail PharmaciesHospitalsOthers

Based on the geographical location, the market is segregated into

Asia Pacific: China, Japan, India, and Rest of Asia PacificEurope: Germany, the UK, France, and Rest of EuropeNorth America: The US, Mexico, and CanadaLatin America: Brazil and Rest of Latin AmericaMiddle East & Africa: GCC Countries and Rest of Middle East & Africa

DataIntelo provides yearly updates on the Neuropathy Pain Treatment market that assist the clients to stay ahead in the competitive space.

Why one should buy this Neuropathy Pain Treatment Report?

The market research report provides all valuable constituents of the market such as revenue growth, product pricing & analysis, growth potential, and guidelines to tackle the challenges in the market. The report covers all the crucial mergers & acquisitions, partnerships, and collaborations that created further created opportunities or in some cases, challenges for the industry players.

This report includes latest product news, advancements, and updates from the prominent player of the industry that has leveraged their position in the market. It also provides business strategies implemented by the key players and yardstick to arrive on informed business decisions. Moreover, it gives insights on the consumer behavior patterns that can help the enterprise to curate the business strategies accordingly.

DataIntelo bestows the clients with the specialized customized options related to the regional analysis, company analysis, and product analysis, among others.

Complete Table Content of the Market

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Neuropathy Pain Treatment Market Overview

Neuropathy Pain Treatment Supply Chain Analysis

Neuropathy Pain Treatment Pricing Analysis

Global Neuropathy Pain Treatment Market Analysis and Forecast by Type

Global Neuropathy Pain Treatment Market Analysis and Forecast by Application

Global Neuropathy Pain Treatment Market Analysis and Forecast by Sales Channel

Global Neuropathy Pain Treatment Market Analysis and Forecast by Region

North America Neuropathy Pain Treatment Market Analysis and Forecast

Latin America Neuropathy Pain Treatment Market Analysis and Forecast

Europe Neuropathy Pain Treatment Market Analysis and Forecast

Asia Pacific Neuropathy Pain Treatment Market Analysis and Forecast

Asia Pacific Neuropathy Pain Treatment Market Size and Volume Forecast by Application

Middle East & Africa Neuropathy Pain Treatment Market Analysis and Forecast

Competition Landscape

If you have any questions on this report, please reach out to us @ https://dataintelo.com/enquiry-before-buying/?reportId=43829

About the Company

DataIntelo is the largest aggregator of the market research report in the industry with more than 800 global clients. The company has extensively invested in the research analysts training and programs to keep the analyst tapped with the best industry standards and provide the clients with the&utmost experience. Our dedicated team has been collaborating with the industry experts to give out the precise data and figures related to the industry. It conducts primary research, secondary research, and consumer surveys to provide an in-depth analysis of the market. The market research firm has worked in several business verticals and has been successful to earn high credentials over the time.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

View post:
Neuropathy Pain Treatment Market 2020 Determined By Manufacturing Summary, Business Profile And Estimate To 2026 - Khabar South Asia

To evaluate the effectiveness of dorsal root ganglion neurostimulation for the treatment of refractory, focal pain in the pelvis and lower extremities.Systematic review.The primary outcome was 50% pain relief. Secondary outcomes were physical function, mood, quality of life, opioid usage, and complications.One pragmatic randomized controlled trial, four prospective cohort studies, and eight case series met the inclusion criteria. A worst-case scenario analysis from the randomized controlled trial reported 50% pain relief in 74% of patients with dorsal root ganglion neurostimulation vs. 51% of patients who experienced at least 50% relief with spinal cord stimulation at 3 months. Cohort data success rates ranged from 43% to 83% at 6 months and 27% to 100% at >6 months. Significant improvements were also reported in the secondary outcomes assessed, including mood, quality of life, opioid usage, and health care utilization, though a lack of available quantitative data limits further statistical analysis. Complication rates vary, though the only randomized controlled trial reported a higher rate of adverse events than that seen with traditional neurostimulation.In accordance with the Grades of Recommendation, Assessment, Development, and Evaluation system, low-quality evidence supports dorsal root ganglion neurostimulation as a more effective treatment than traditional neurostimulation for pain and dysfunction associated with complex regional pain syndrome or causalgia. Very low-quality evidence supports dorsal root ganglion neurostimulation for the treatment of chronic pelvic pain, chronic neuropathic groin pain, phantom limb pain, chronic neuropathic pain of the trunk and/or limbs, and diabetic neuropathy. The Author(s) 2020. Published by Oxford University Press on behalf of the American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

PubMed

Read more:
The Effectiveness of Dorsal Root Ganglion Neurostimulation for the Treatment of Chronic Pelvic Pain and Chronic Neuropathic Pain of the Lower...

Winter can be hard for many people, but for cancer patients, slippery streets, and cold weather are more than a hazard, they can also be a health risk. Learn how cold weather affects cancer patients and how they can stay safe during the winter.

HypothermiaHypothermia is a condition where the human body begins to lose heat faster than it can produce it, causing the body temperature to become dangerously low. Side effects of cancer treatment, such as fatigue, dehydration, and anemia, can make patients more susceptible to hypothermia.

FrostbiteSome treatments can cause peripheral neuropathy, which carries numbness in the extremities as a potential side effect. Patients who have peripheral neuropathy are more likely to get frostbite since they cant feel how cold their fingers and hands are in cold weather.

FallsPatients can have a higher risk of fracture if they are receiving treatments that affect bone density. Cancer patients need to be especially careful if they have thrombocytopenia, a condition associated with blood cancers that cause low platelet counts. Since platelets help blood clot, a low count can mean that bruising or serious bleeding can happen when injured.

Patients who have numbness in their feet (neuropathy) are also more prone to falls.

FluCancer therapy may weaken patients immune systems. It is necessary that they get their flu shot since they dont have enough white blood cells to fight infections. This is why cancer patients have a higher chance of having complications from the flu than a healthy person.

Tips to Stay SafeFollow these tips to protect your health or a loved one in winter and stay safe:

If youd rather avoid winter and the risks it carries for cancer patients, you can always consider health tourism. Its the practice of traveling to a popular tourist destination with the purpose of receiving therapeutic treatment. For example, Florida has mild, pleasant winters, which make it an ideal location for health tourism!

Winter wont last forever, even if you sometimes feel that way, so celebrate each sunny day!

More than a thousand men and women diagnosed with cancer each year turn to our trusted team of cancer specialists at Tampa Bay Radiation Oncology. We encourage you to call us, ask us a question, or consult with us to get a second opinion so you, too, can experience the difference.

Featured image: Winter. Photo courtesy: 2020 Pixabay/Ina Hoekstra (Heerenveen, The Netherlands)

Read more from the original source:
How Cold Weather Affects Cancer Patients - OncoZine

New Jersey, United States: Market Research Intellect has added a new report to its huge database of research reports, entitled Diabetic Peripheral Neuropathy Treatment Market Size and Forecast to 2027. The report offers a comprehensive assessment of the market including insights, historical data, facts, and industry-validated market data. It also covers the projections using appropriate approximations and methods.

Diabetic Peripheral Neuropathy Treatment Market Overview

The Diabetic Peripheral Neuropathy Treatment Market Report provides comprehensive data on market dynamics, market trends, product growth rate, and price. The Diabetic Peripheral Neuropathy Treatment market report has various facts and statistics assuming the future predictions of the upcoming market participants. In addition, it offers business security taking into account sales, profit, market volume, demand and market supply ratio. The in-depth study provides vital information related to market growth, driving factors, major challenges, opportunities, and threats that will prove to be very helpful for market participants in making upcoming decisions.

Diabetic Peripheral Neuropathy Treatment Market: Competitive Landscape

The Diabetic Peripheral Neuropathy Treatment Market report consists of the Competitive Landscape section which provides a complete and in-depth analysis of current market trends, changing technologies, and enhancements that are of value to companies competing in the market. The report provides an overview of sales, demand, futuristic costs and data supply as well as a growth analysis in the forecast year. The key vendors in the market that are performing the analysis are also clearly presented in the report. Their development plans, their growth approaches, and their merger and acquisition plans are also identified. Information specific to a keyword in each of these regions is also provided. This report also discusses the submarkets of these regions and their growth prospects.

Prominent players operating in the market:

Diabetic Peripheral Neuropathy Treatment Market Segmentation

The report contains the market size with 2019 as the base year and an annual forecast up to 2027 in terms of sales (in million USD). For the forecast period mentioned above, estimates for all segments including type and application have been presented on a regional basis. We implemented a combination of top-down and bottom-up approaches to market size and analyzed key regional markets, dynamics and trends for different applications.

Diabetic Peripheral Neuropathy Treatment Market Segment by Type:

Diabetic Peripheral Neuropathy Treatment Market Segment by Application:

Diabetic Peripheral Neuropathy Treatment Market Regional overview:

In the report, experts analyze and forecast the Diabetic Peripheral Neuropathy Treatment market on a global as well as regional level. Taking into account all aspects of the market in terms of regions, the focus of the report is on North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The prevailing trends and various opportunities in these regions are studied that can convince the growth of the market in the forecast period 2020 to 2027.

Reasons to Buy the Diabetic Peripheral Neuropathy Treatment Market Report:

Outlook analysis of the Diabetic Peripheral Neuropathy Treatment market sector with current trends and SWOT analysis. This study evaluates the dynamics, competition, industrial strategies and strategies of the emerging countries. This report has a comprehensive guide that provides market insights and detailed data on each market segment Market growth factors and risks are presented. More precise information provision on the Diabetic Peripheral Neuropathy Treatment market for different countries. Provide visions on factors influencing the growth of the market. Market segmentation analysis, including quantitative and qualitative research considering the impact of economic and non-economic aspects Comprehensive company profiles with product offerings, important financial information and the latest developments.

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

Go here to see the original:
Diabetic Peripheral Neuropathy Treatment Market Size, Analysis, Growth, Trends, Outlook And Forecast By 2027 - The Haitian-Caribbean News Network

As we attempt to protect our elderly population in this pandemic, this is what I see when I look through the window,

I look into the window as she awakens to the sound of business outside the door. I can tell that she is not sure who is outside her door. For that matter not sure of the day or time. Is it Wednesday, or Saturday. They all seem the same, day after day unchanging. Someone enters her room with very little conversation. No small talk, places her breakfast box on the tiny table by her chair. I see her say hello and smile at the woman, she just turns to leave. She slowly opens the Styrofoam box to find watery eggs and sausage and a cup of coffee. Her neuropathy wont allow her to open the sugar that she would love to have added to her coffee, but the woman is already gone. She tries to open it but finally puts it down and she just drinks it black. I watch her struggle to eat a few bites of the eggs, dropping them on her shirt. I think she finally figured it is morning. I see she has her TV on, but I know she cant hear much of the show as she is hearing impaired. I notice it has the closed caption on again. I guess she was trying to change the channel. She just cant use that remote and I cant get in to change it myself. She just sits listlessly staring ahead. Loneliness. Is what I see!

I knock on her window to get her attention. She finally looks up. She smiles, it makes me sad to see her happy just to see me through the window, but it is all I can do. Her hair is so disheveled. She would have never looked like this. She always had a standing appointment at the beauty shop weekly for a wash and style. But I guess it doesnt matter, she doesnt ever see her hair. She goes nowhere, only sitting in her room. Alone. I wave at her smiling, while fighting back tears. I hold up my phone to motion that I am going to call her room. I can hear it ringing. I watch her slowly reach for the phone. It continues to ring. Again her neuropathy slows her so much my call is forwarded to voice mail. I call back but now get an instant message. She has not ended the previous call. I finally call the facility and ask someone to please go to her room and help her answer the phone. She smiles as she hears my voice. Why cant these phones be like they used to be? Why cant I just answer it when someone calls me so I can talk to them? Can you please find me a phone like I used to have? Why do I have to push buttons? I cant remember which buttons to push. I just cant use this phone.

Another person with face covered, enters the room, hands her some pills and a sip of water. They are quickly gone. Alone again. She asks if I can just come in for a minute, she has something she wants to tell me. I try to explain that I cant come in at all. I would love to, but I am not allowed. I can only watch from outside the window. She tries to tell me something about last night, but her story is hard to follow. She was never like this, always so lucid with organized thought. This is all changing as I watch from outside the window. She again asks if I can get an appointment to see her. I feel like she thinks she is forgotten; the loneliness is overwhelming. She cannot understand why I dont visit.

I see her plant in the window sill, it needs watering. I tell her the plant needs a drink. But I know she cant water it and the people here are too busy she says. We talk about her breakfast, and I tell her I brought her a few goodies they will deliver to her room. She smiles. I finally tell her that Im leaving as it is cold outside. The smile fades and she says again can you come in for just a minute?

This is what I see from the window! This is one visit at her long term care facility. These visits are increasingly painful to watch and be a part of. The longer she is kept from her family, the worse she gets cognitively and physically. I see the sadness. I see the decline in her health through this window. I know there are others seeing the same as they look through their loved ones windows. The only thing these precious people have done wrong is get old. Now they are forced to live out their last days all alone. I understand we are trying to protect the frail and elderly, but is that really what we are doing?

Teresa Peers

* * *

Amen to Teresa Peers! You are not alone in this fight. I know all the facilities are doing their best to keep people safe, but at what cost?

I think many would choose to take a chance on the virus versus the isolation.

From one caregiver to another, I hear you.

Jeannie Hixon

See the article here:
Our Elderly In Isolation - And Response - The Chattanoogan

A once-per-week selinexor (Xpovio), bortezomib (Velcade), plus dexamethasone treatment strategy appeared effective and convenient as treatment of patients with multiple myeloma who received at least 1 to 3 prior lines of therapy, according to findings from the phase 3, randomized, open-label BOSTON trial.

The study was conducted across 123 sites in 21 countries, and patients were randomized 1:1 to 1 of 2 arms; patients received selinexor 100 mg once per week, bortezomib 1.3 mg/m2 once per week, and dexamethasone 20 mg twice per week, or in the second arm, patients were treated with bortezomib 1.3 mg/m2twice per week for the first 24 weeks and once per week thereafter and dexamethasone 20 mg 4 times per week for the first 24 weeks and twice per week thereafter.

The primary end point of the study is progression-free survival (PFS), and secondary end points included objective response rate (ORR), overall survival (OS), and duration of response (DOR), as well as PFS and ORR in patients who crossed over from the control arm, PFS on subsequent line of therapy, time to next anti-multiple myeloma treatment, time to response, incidence of grade 2 or higher peripheral neuropathy events, and patient-reported peripheral neuropathy. Safety and tolerability were also reviewed as additional secondary end points.

The median age of patients in the experimental arm was 66 years (range, 59-72) compared with 67 years (range, 61-74) in the control arm, and the majority of patients were male in both arms (59% and 56%, respectively). Among patients randomized to the triplet arm (n = 195), 54% had an ECOG performance status of 1, 35% 0, and 10% 2, compared with 55%, 37%, and 8% in the control arm, which included 207 patients total. Most patients (51%) had received 1 prior line of therapy in the experimental arm versus 48% in the control, while 33% and 31% had 2 prior lines, and 16% and 21% had 3 prior lines, respectively.

Overall, the PFS was significantly longer with the triplet regimen compared with bortezomib and dexamethasone alone. The median PFS was 13.93 months (95% CI, 11.73-not evaluable [NE]) in the experimental arm versus 9.46 months (95% CI, 8.11-10.78) in the control arm (HR, 0.70; 95% CI, 0.53-0.93; P=.0075).

The ORR was significantly higher with the once-per-week regimen at 76.4% (95% CI, 69.8-82.2) compared with 62.3% (95% CI, 55.3-68.9) in the control arm (OR, 1.96; 95% CI, 1.3-3.1; P =.0012). In the triplet arm, the proportion of patients with a very good partial response or was 44.6% (95% CI, 37.5-51.9) compared with 32.4% (95% CI, 26.0-39.2) in the bortezomib plus dexamethasone arm (OR, 1.66; 95% CI, 1.1-2.5; P =.0082). The proportion of patients with stable disease or progressive disease as their best response was also lower in the triplet arm at 13.3% (95% CI, 8.9-18.9) compared with 24.2% in the control arm (95% CI, 18.5-30.6).

The median time to first response of a partial response or better was 1.1 months (interquartile range [IQR], 0.8-1.6) in the triplet arm versus 1.4 months (IQR, 0.8-1.6) in the control arm. The median duration of response was longer with the once-per-week regimen at 20.3 months (95% CI, 12.5-NE) compared with 12.9 months (95% CI, 9.3-15.8) in the control (HR, 0.81; 95% CI, 0.56-1.17; P =.1364). The median time to next anti-myeloma therapy was longer in the triplet arm as well at 10.8 months (95% CI, 9.8-13.4) versus 0.66 (95% CI, 0.50-0.86) in the control (P =.0012).

Overall, 47 patients (24%) died in the experimental arm compared with 62 (30%) in the control arm. The median OS was not reached after a median follow-up of 17.3 months in the triplet arm (IQR, 12.9-20.3) versus 25 months (95% CI, 23.5-NE) after 17.5 months follow-up in the experimental arm (HR, 0.84; 95% CI, 0.57-1.23; P =.1852).

In the safety analysis, 195 patients from the triplet arm and 204 from the doublet arm were included. The most common treatment-emergent adverse events (AEs) of grade 3/4 included thrombocytopenia (39% vs 17%), anemia (16% vs 10%, pneumonia (12% vs 10%), and fatigue (13% vs 1%), and these all occurred in higher incidences in the triplet arm compared with the control, respectively.

Treatment was discontinued in 41 (21%) of patients in the experimental arm versus 32 (16%) in the control arm due to treatment-emergent AEs. The most common reasons for treatment discontinuation included peripheral neuropathy (5%), fatigue (4%), nausea (3%), vomiting (2%), decreased appetite (2%), and thrombocytopenia (2%) in the triplet arm, and the most common reason in the control arm was peripheral neuropathy (7%).

The median time to treatment discontinuation was 194 days (IQR, 100-332) in the experimental arm versus 184 (IQR, 106-276) in the control arm, and among all patients who had discontinued, 19 (46%) in the once-per-week arm and 16 (50%) in the bortezomib and dexamethasone arm were over the age of 70 years.

Dose modifications were common in the triplet arm, occurring in 173 (89%) of patients compared with 156 (76%). Most of the side effects that were associated with selinexor were reversible and were mitigated with standard supportive care.

Serious AEs occurred in 101 (52%) of patients in the once-per-week arm versus 77 (38%) in the control arm, and the most frequent serious AE was pneumonia, occurring in 12% of each arm.

Overall, this study demonstrated a significant increase in PFS for patients previously treated with multiple myeloma when treated with the triplet versus the control arm of bortezomib with dexamethasone. The benefit was observed across subgroups, and the improved efficacy was particularly notable in that it was achieved during the first 24 weeks of therapy, according to the study authors.

Reference

Grosicki S, Simonova M, Spicka I, et al.Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.Lancet. 2020;396(10262):P1563-1573. doi: 10.1016/S0140-6736(20)32292-3

More here:
Once-Per-Week Selinexor Triplet Appears Effective in Patients With Multiple Myeloma - Targeted Oncology

Ischemic optic neuropathy is caused due to a small vessel infraction of the optic nerve and is a major cause of blindness or impaired vision among the inflicted. There are two types of ischemic optic neuropathies viz. anterior ischemic optic neuropathy and posterior or non-anterior ischemic optic neuropathy. Anterior ischemic optic neuropathy is caused by the inflammation of arteries supplying blood to the optic nerve whereas posterior or non-anterior ischemic optic neuropathy is caused due to reasons other than inflammation of the arteries. Anterior ischemic optic neuropathy is more prevalent as compared to posterior ischemic optic neuropathy. In anterior ischemic optic neuropathy, immediate treatment is required to prevent vision loss in the fellow eye as approximately 50 percent of cases have chances of blindness in another eye within a span of 5 to 10 days without treatment. The symptoms of ischemic optic neuropathy include unilateral, acute and painless visual loss for hours to days. Hypertension, diabetes, and hypercholesterolemia are some of the well-known risk factors associated with ischemic optic neuropathy disease. Other factors include generalized hypoperfusion, sleep apnea, nocturnal hypotension, vasospasm, severe anemia and failure of autoregulation.

To remain ahead of your competitors, request for a sample [emailprotected]https://www.persistencemarketresearch.com/samples/23077

Technological advancements in ischemic optic neuropathy treatment and availability of alternative drugs are anticipated boost the demand for ischemic optic neuropathy treatments over the forecast period.

The global ischemic optic neuropathy treatment market can be segmented on the basis of disease type, treatment type and end user.

On the basis of disease type, the global ischemic optic neuropathy treatment market can be segmented into:

On the basis of treatment type, the global ischemic optic neuropathy treatment market can be segmented into:

On the basis of end user, the global ischemic optic neuropathy treatment market can be segmented into:

To receive Methodology request here@https://www.persistencemarketresearch.com/methodology/23077

The global ischemic optic neuropathy treatment market is expected to register a significant CAGR over the forecast period. The increasing adoption of recently approved intravitreal implants in the treatment of ophthalmology diseases is anticipated to propel the growth of the ischemic optic neuropathy treatment market over the forecast period. Leading pharmaceutical and drug manufacturing companies from developed countries are substantially investing in R&D, infrastructure and new technologies in ophthalmology therapeutics to capture a market share in the growing burden of eye diseases, which also boosts the growth of the global ischemic optic neuropathy treatment market. With growing awareness towards eye-related complications that lead to blindness, geriatric population and diabetic patients in developed countries, such as the U.S., Russia, and Poland, Germany and Japan are seen to have a proactive approach for treatment related to complications rather than reactive treatment, which also bolsters the growth of the market of ischemic optic neuropathy treatment.

Corticosteroid is the first choice of therapy for patients with ischemic optic neuropathy in prominent countries, such as the U.S., Germany, France, and Russia; however, a majority of patients have developed resistance to anti-VEGF, which leads to the adoption of alternative therapy in patients with ischemic optic neuropathy. This is anticipated to drive the growth of the global ischemic optic neuropathy treatment market in the long run.

To receive extensive list of important regions, Request TOC here @https://www.persistencemarketresearch.com/toc/23077

However, medications such as intravitreal injections of anti-VEGF drugs and corticosteroids lead to an instant increase in intraocular pressure, which may lead to severe adverse effects such as conjunctival haemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased and vitreous detachment. This may restrain the growth of the global ischemic optic neuropathy treatment market.

On the basis of regional presence, the global ischemic optic neuropathy treatment market can segmented into five key regions, namely North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa.

North America is a dominant region in the market and contributes a leading share to the global ischemic optic neuropathy treatment market in terms of revenue. The market in the region is expected to register significant growth over the forecast period due to the availability of developed medical infrastructure and treatment facilities in the region. Europe also contributes a moderate share and registered a healthy growth rate in the global ischemic optic neuropathy treatment market. The APEJ region has become a lucrative market for ischemic optic neuropathy treatment and is anticipated to register a significant share over the forecast period, due to the increase in research and development activities along with the growth in medical tourism in the region. Latin America and MEA are in the nascent stage in the global ischemic optic neuropathy treatment market and are expected to register moderate growth over the forecast period.

Some of the market players operating in the ischemic optic neuropathy treatment market include

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Read more:
The Ischemic Optic Neuropathy Treatment Market to remain unfazed by the Global Recession - Khabar South Asia